Submitted:
20 December 2023
Posted:
21 December 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
- Despite introducing more targeted HIV testing approaches such partner testing services in Uganda, the overall HTS yield remained relatively constant from 3.1% in 2017, peaking at 3.8% in 2018 and regressing to 3.1% in 2019. Whereas index testing (including partner testing services) provided a positivity rate of 20% in 2019, the overall contribution to case identification by this HTS modality was only 15.4%, with provider-initiated counselling and testing other (PITC-other) modality contributing 53% of all HIV-positive cases identified in 2019 (5). Large facility-based entry points like PITC, however, reach large numbers of clients and identify more PLHIV in absolute numbers than targeted strategies, even if they are of lower yield. As a result, in recent years, the vast majority of newly identified PLHIV have been identified through facility-based testing (6). For example, in 2018, PITC at outpatient departments (OPD) and facility-based voluntary counselling and testing (VCT) accounted for approximately 68% of all newly diagnosed PLHIV (7).
-
Does the patient have co-morbidities or an exposure risk?
- Presumptive TB
- New perpetuators and survivors of SGBV
- A reactive HIV self-test
- Elicited through index testing
- Accidentally exposed to HIV
- Diagnostic HTS (unconscious, critically ill, mentally impaired)
- Has the client had an HIV test in the last 12 months?
- Has the client tested within the last 3 months?
- Client has had unprotected sex with partner(s) of unknown HIV status or known HIV positive status since the last negative HIV test?
- HIV negative partner(s) in a discordant relationship and has not had an HIV test within the past 3 months
- Client has diagnosis of sexually transmitted infection (including Hepatitis B) after previous negative HIV test
- Client with TB, STI, Hepatitis B, symptomatic of HIV, or is on PEP and Tested HIV Negative at least 1 month ago
2. Materials and Methods
Design
Settings
Study participants
Study variables
Sample size and data sources
Data analysis
Ethical considerations
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Muttai H, Guyah B, Achia T, Musingila P, Nakhumwa J, Oyoo R, et al. Mapping geographic clusters of new HIV diagnoses to inform granular-level interventions for HIV epidemic control in western Kenya. BMC Public Health. 2021, 21.
- UNAIDS. UNAIDS DATA 2021. Retrieved from https://www.unaids.org/sites/default/files/media_asset/JC3032_AIDS_Data_book_2021_En.pdf. 2021.
- De Cock KM, Barker JL, Baggaley R, El Sadr WM. Where are the positives? HIV testing in sub-Saharan Africa in the era of test and treat. AIDS. 2019;33(2).
- PEPFAR. PEPFAR 2020 Country Operational Plan Guidance for all PEPFAR Countries. Retrieved from https://www.state.gov/wp-content/uploads/2020/01/COP20-Guidance_Final-1-15-2020.pdf. 2020.
- Uganda AIDS Commission. Empowering Young People to Champion the End of New HIV Infections. In: Health, editor. Uganda2020.
- Martelli G, Van Duffel L, Kwezi EC, Cavallin F, Salehe IA, Torelli GF, et al. Community- and facility-based HIV testing interventions in northern Tanzania: Midterm results of Test & Treat Project. PLoS One 2022, 17, e0266870.
- PEPFAR. PEPFAR Uganda Country Operational Plan (COP) 2019-Strategic Direction Summary. In: Health, editor.: PEPFAR; 2019.
- Bandason T, Dauya E, Dakshina S, McHugh G, Chonzi P, Munyati S, et al. Screening tool to identify adolescents living with HIV in a community setting in Zimbabwe: A validation study. PLoS One 2018, 13, e0204891.
- Muttai H, Guyah B, Musingila P, Achia T, Miruka F, Wanjohi S, et al. Development and Validation of a Sociodemographic and Behavioral Characteristics-Based Risk-Score Algorithm for Targeting HIV Testing Among Adults in Kenya. AIDS Behav. 2021, 25, 297–310. [CrossRef] [PubMed]
- Powers KA, Miller WC, Pilcher CD, Mapanje C, Martinson FE, Fiscus SA, et al. Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm. Aids 2007, 21, 2237–42. [CrossRef] [PubMed]
- Antelman G, Gill MM, Jahanpour O, van de Ven R, Kahabuka C, Barankana A, et al. Balancing HIV testing efficiency with HIV case-identification among children and adolescents (2-19 years) using an HIV risk screening approach in Tanzania. PLoS One 2021, 16, e0251247.
- Mugauri HD, Chirenda J, Takarinda K, Mugurungi O, Ncube G, Chikondowa I, et al. Optimising the adult HIV testing services screening tool to predict positivity yield in Zimbabwe, 2022. PLOS Global Public Health 2022, 2, e0000598.
- Soh QR, Oh LYJ, Chow EPF, Johnson CC, Jamil MS, Ong JJ. HIV Testing Uptake According to Opt-In, Opt-Out or Risk-Based Testing Approaches: a Systematic Review and Meta-Analysis. Current HIV/AIDS Reports. 2022, 19, 375–83. [CrossRef] [PubMed]
- Quinn C, Wong V, Jamil MS, Baggaley RC, CC. J. Web Annex L. Symptom and risk-based screening to optimize HIV testing services: a scoping review. Consolidated guidelines on HIV testing services, 20192020.
- Grimsrud A, Wilkinson L, Ehrenkranz P, Behel S, Chidarikire T, Chisenga T, et al. The future of HIV testing in eastern and southern Africa: Broader scope, targeted services. PLoS Med. 2023, 20, e1004182.
- Ong JJ, Coulthard K, Quinn C, Tang MJ, Huynh T, Jamil MS, et al. Risk-Based Screening Tools to Optimise HIV Testing Services: a Systematic Review. Curr HIV/AIDS Rep. 2022, 19, 154–65. [CrossRef] [PubMed]
- Nichols BE, de Nooy A, Benade M, Balakasi K, Mphande M, Rao G, et al. Facility-based HIV self-testing strategies may substantially and cost-effectively increase the number of men and youth tested for HIV in Malawi: results from an individual-based mathematical model. J Int AIDS Soc. 2022, 25, e26020.

| Characteristics | All | HIV Status | Univariate OR (95% CI) | p value | |
|---|---|---|---|---|---|
| Positive | Negative | ||||
| N=19,704 | n= 732 (%col) | n= 18,972(%col) | |||
| Age (years) | |||||
| 15-19 | 3,379 (17%) | 42 (6%) | 3,337 (17%) | 1 | <.001 |
| 20-35 | 11,469 (58%) | 457 (62%) | 11,012 (58%) | 3.10 (2.08-4.63) | |
| 36-50 | 3,310 (17%) | 171 (24%) | 3,139 (17%) | 4.21 (2.78-6.35) | |
| 50+ | 1,546 (8%) | 62 (9%) | 1,484 (8%) | 3.33 (2.00-5.56) | |
| Median age (IQR) | 27 (21-35) | 30 (25-39) | 26 (21-35) | ||
| Gender | |||||
| Female | 12,971 (66%) | 475 (65%) | 12,496 (66%) | 1 | 0.7762 |
| Male | 6,733 (34%) | 257 (35%) | 6,476 (34%) | 1.01 (0.83-1.24) | |
| Marital Status | |||||
| Married | 12,071 (61%) | 464 (63%) | 11,607 (61%) | 1 | <.001 |
| Divorce/ Separated | 1,544 (8%) | 115 (16%) | 1,429 (8%) | 2.11 (1.59-2.81) | |
| Single | 5,628 (29%) | 128 (18%) | 5,500 (29%) | 0.60 (0.43-0.85) | |
| Widowed | 461 (2%) | 25 (3%) | 436 (2%) | 1.60 (0.88-2.88) | |
|
Screened and eligible for testing |
|||||
| Yes | 14,879 (76%) | 664 (91%) | 14,215 (75%) | 3.60 (2.30-5.62) | |
| No | 4,825(24%) | 68(9%) | 4,757(25%) | 1 | <.001 |
| Variable | Tested (n) | Positive (n) |
Positivity Rate (n/n%, 95% ci) |
|---|---|---|---|
| Positivity rate | |||
| Without risk screening | 19,704 | 732 | 3.7% |
| With risk screening (screened in) | 14,879 | 664 | 4.5% |
| With risk screening (screened out) | 4,825 | 68 | 1.4% |
| Diagnostic characteristics of the tool | (N) | (n) | (n/N%, 95% CI) |
| Sensitivity | 732 | 68 | 90.7%, (88.4-92.7) |
| Specificity | 19,636 | 14,879 | 75.8%, (75.2-76.4) |
| Predictive value positive | 12.3%, (11.9-12.6) | ||
| Predictive value negative | 99.6% (99.4-99.6) | ||
| Number needed to test | |||
| Number needed to test without screening | 3.7 | 1 | 27 |
| Number needed to test with screening | 4.5 | 1 | 22 |
| Positive likelihood ratio | 24.2 | 90.7 | 3.74, (3.6-3.9) |
| Negative likelihood ratio | 75.8 | 9.3 | 0.12, (0.10-0.15) |
| Eligible (%) | HIV positivity (%) | Sensitivity | PLHIV missed (%) | |
|---|---|---|---|---|
| (95% CI) | ||||
| NO HIV test in the last 12 months | 6,880 (35%) | 314 (4.6%) | 42.9% (39.3-46.6) | 418 (57.1%) |
| Patient belongs to one of 6 categories in Question 1 of screening tool | 936 (5%) | 104 (11.1%) | 14.2% (11.8-16.9) | 628 (85.8%) |
| Tested in the last 12 months, but not in the last 3 months | 4,314 (22%) | 138 (3.2%) | 18.9% (16.1-21.9) | 594 (81.1%) |
| Client has had unprotected sex with partner(s) of unknown HIV status or known HIV positive status since the last negative HIV test? | 3,281 (17%) | 160 (4.9%) | 21.9% (18.9-25.0) | 572 (78.1%) |
| HIV negative partner(s) in a discordant relationship and has not had an HIV test within the past 3 months | 384 (2%) | 36 (9.4%) | 4.9% (3.5-6.7) | 696 (95.1%) |
| Client has diagnosis of sexually transmitted infection (including Hepatitis B) after previous negative HIV test | 528 (3%) | 21 (4.0%) | 2.9% (1.8-4.4) | 711 (97.1%) |
| Client with TB, STI, Hepatitis B, symptomatic of HIV, or is on PEP and tested HIV Negative at least 1 month ago | 750 (4%) | 44 (5.9%) | 6.0% (4.4-8.0) | 688 (94%) |
| Screening tool (Yes to any above question) | 14,885 (76%) | 664 (4.46%) | 90.7% (88.4-92.7) | 68 (9.3%) |
| No screening tool | 19,717 | 732 (3.71%) |
| HR and commodity costs for current standard of care compared with screening in OPD | |||
| Standard of Care | Screening in OPD | Screening tool savings | |
| Total number of tests (A1) | 19,704 | 16,764 | 2,951 |
| Total cost | $44,357 | $40,222 | $4,138 |
| Commodities | $25,825 | $22,036 | $3,790 |
| Human resources | $18,532 | $18,184 | $348 |
| Cost per PLHIV identified | $69.05 | $66.91 | $2.14 |
| Commodity cost per PLHIV identified | $40.2 | $34.4 | $5.9 |
| Human resources per PLHIV identified | $28.85 | $28.31 | $0.54 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).